Comparison of Two Different Sperm Processing Methods and Their Effects on Sperm DNA Fragmentation and Embryo Development

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-34
SponsorRichard Kordus, PhD, HCLD (ABB)

About this trial

The goal of this clinical trial is to learn if the LensHooke CA0 device lowers DNA fragmentation in sperm samples compared to a gradient/swim-up technique.

The main questions it aims to answer are:

1. Does the LensHooke® CA0 device reduce DNA fragmentation compared to the gradient/swim-up technique? 2. Does the LensHooke® CA0 device improve concentration, motility, and morphology compared to the gradient/swim-up technique? 3. Is sibling embryo fertilization and development the same? 4. Are pregnancy rates different between the 2 groups?

1 semen sample will be split between the 2 treatment techniques. Half of the partner's egg cohort will be injected via intra-cytoplasmic sperm using sperm processed by one technique and the other half of the cohort will be injected by the sperm processed by the other technique. Both methods will look at DNA fragmentation, concentration, motility, and morphology of the sperm. Both methods will be compared in the resulting embryos looking at fertilization, embryo development and pregnancy rates.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Samples with ≥15 M/mL spermatozoa concentration

Female partner between 18 and 34 years old.

Minimum of 4 fertilized eggs in gradient/swim prep group and 4 fertilized eggs in the Lenshooke prep group for each patient

Disqualifiers

Samples with <15 M/mL spermatozoa concentration

female partner >35 years old

female patient with recurrent pregnancy loss

female patient with diminished ovarian reserve

Trial design

Design model

Single group

Treatments tested in this trial

  • sperm separation device

    Device

    comparison of DNA damage between the 2 interventions and subsequent embryo development and pregnancy rates

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: Gradient/swim-up vs Lenshooke CA0 device comparisonExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Percentage of sperm with DNA fragmentation

The method is based on the Sperm Chromatin Dispersion (SCD) test (Fernández et al., J. Androl 24:59-66, 2003; Fertil Steril 84:833-842, 2005). Intact unfixed spermatozoa (fresh, frozen/unthawed, diluted or neat samples) are immersed in an inert agarose microgel on a pretreated slide. An initial acid treatment denatures DNA in those sperm cells with fragmented DNA. Following this, the lysing solution removes most of the nuclear proteins, and in the absence of massive DNA breakage produces nucleoids with large halos of spreading DNA loops, emerging from a central core. However, the nucleoids from spermatozoa with fragmented DNA either do not show a dispersion halo or the halo is minimal. Slides are stained with Wright's stain. A minimum of 300 sperm per sample will be counted. The percentage of sperm with fragmented DNA will be calculated by dividing the sperm with small and no halos (fragmented sperm) by the total number of sperm counted.

Time frame
From enrollment until day after sample collection, approximately 1 month

Secondary outcomes

1

Concentration of sperm per mL

Assessed using a sperm class analyzer - SCA (CASA system) for sperm count. Semen samples will be loaded into 20 microliter depth fixed volume slides. Slides will be placed on the Microoptics SCA machine. Videos will be captured of fields until at least 200 motile sperm are captured. Concentration will be analyzed by counting the number of sperm within each field, corrected for the depth of the chamber, and multipled by the volume of the sample. Concentrations between fields will not vary by more than 15%.

Time frame
From enrollment until day after sample collection, approximately 1 month

Other outcomes

1

Percentage of motile sperm

Assessed using a sperm class analyzer - SCA (CASA system) for sperm motility. Semen samples will be loaded into 20 microliter depth fixed volume slides. Slides will be placed on the Microoptics SCA machine. Videos will be captured of fields until at least 200 motile sperm are captured. Motility will be calculated as the number of motile sperm counted divided by the total number of sperm counted. Types of motility will be noted according to WHO semen analysis groupings, hyperactivation, and kinetic motion parameters.

Time frame
From enrollment until day after sample collection, approximately 1 month
2

Percentage of Sperm with normal morphology Using Kruger Strict Criteria

10 uL volumes of sperm samples will be placed on pre-stained morphology slides using methylene blue/cresyl violet stain. A minimum of 200 sperm will be counted and assessed for normal vs abnormal sperm morphology using Kruger strict criteria. Percentage of normal sperm will be assessed my dividing the number of normal sperm by the total number of sperm counted.

Time frame
From enrollment until day after sample collection, approximately 1 month
3

Percentage of egg fertilization

The number of fertilized eggs (zygotes) will be divided by the number of eggs inseminated

Time frame
From enrollment until a week after sample collection, approximately 5 weeks
4

Numerical score of morphokinetic embryo development

Embryo development will be monitored using a time-lapse incubator. A score will be generated based on when the embryos meets developmental time points. The embryo will receive 2 points for each time point it successfully completes with expected parameters. Embryos will receive 1 point for each time point it completes but outside the expected time parameters. i.e. if an embryo has the first cleavage between 23-25 hours it will receive 2 points. If it cleaves earlier than 23 hours or later than 25 hours it will receive 1 point. The total score an embryo receives will be tallied from the time of insemination until the embryo is frozen.

Time frame
From enrollment until a week after sample collection, approximately 5 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Richard Kordus, PhD, HCLD (ABB)

Lead sponsor

Prisma Health-Upstate

Sponsor institution